Manager TitleAgeSince
Chief Executive Officer 39 01/01/2016
Director of Finance/CFO 54 03/10/2023
Corporate Secretary - 13/10/2023
Director TitleAgeSince
Chairman 62 06/01/2023
Director/Board Member 75 22/09/2021
Director/Board Member 67 22/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Buy

Director

20,000 0.0242%
02/09/24 Sell

Director

20,000 0.0242%
13/08/24 Free

Executive/Senior Manager

320,000 0.3878%
Change 5-day change 1-year change 3-year change Capi.($)
+17.65%+33.33% - - 10.49M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average +0.53%-1.22%+33.07%+180.54% 44B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%
Logo BiVictriX Therapeutics plc
BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Company’s novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.
Employees
-